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Abstract
Background: Antiretroviral therapy (ART) improves morbidity and mortality in patients with HIV, however high rates of loss
to follow-up (LTF) and mortality have been documented in HIV care and treatment programs.
Methods: We analyzed routinely-collected data on HIV-infected patients $15 years enrolled at 41 healthcare facilities in
Rwanda from 2005 to 2010. LTF was defined as not attending clinic in the last 12 months for pre-ART patients and 6 months
for ART patients. For the pre-ART period, sub-distribution hazards models were constructed to estimate LTF and death to
account for competing risks. Kaplan-Meier (KM) and Cox proportional hazards models were used for patients on ART.
Results: 31,033 ART-naı̈ve adults were included, 64% were female and 75% were WHO stage I or II at enrollment. 17,569
(56%) patients initiated ART. Pre-ART competing risk estimates of LTF at 2 years was 11.2% (95%CI, 10.9–11.6%) and 2.9% for
death (95%CI 2.7–3.1%). Among pre-ART patients, male gender was associated with higher LTF (adjusted sub-hazard ratio
(aSHR) 1.3, 95%CI 1.1–1.5) and death (aSHR 1.7, 95%CI 1.4–2.1). Low CD4 count (CD4,100 vs. $350 aSHR 0.2, 95%CI 0.1–0.3)
and higher WHO stage (WHO stage IV vs. stage I aSHR 0.4, 95%CI 0.2–0.6) were protective against pre-ART LTF. KM estimates
for LTF and death in ART patients at 2 years were 4.4% (95%CI 4.4–4.5%) and 6.3% (95%CI 6.2–6.4%). In patients on ART,
male gender was associated with LTF (adjusted hazard ratio (AHR) 1.4, 95%CI 1.2–1.7) and death (AHR1.3, 95%CI 1.2–1.5).
Mortality was higher for ART patients $40 years and in those with lower CD4 count at ART initiation.
Conclusions: Low rates of LTF and death were founds among pre-ART and ART patients in Rwanda but greater efforts are
needed to retain patients in care prior to ART initiation, particularly among those who are healthy at enrollment.
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Introduction
The introduction of antiretroviral treatment (ART) has
dramatically improved the survival of people living with HIV.
Expansion of HIV care and treatment programs has been a
priority for governments in high burden countries and there are
now over 8 million adults and children receiving ART
worldwide.[1] Rwanda has achieved considerable success in
scaling up HIV care and treatment services.[2–4] By the end of
2010, Rwanda was one of only 3 low- and middle-income
countries with generalised HIV epidemics that had achieved and
surpassed the World Health Organization’s definition of universal
ART access with 88% of those in need receiving treatment.[4]
These accomplishments were made through a multi-pronged
national strategy based on decentralisation of services,[5] provision
of free ART,[2] involvement of peer educators and task shifting to
nurse-provided care,[3,4,6] as well as collaboration with partner
organizations.[7]
A critical issue for HIV care and treatment programs is
retention of patients between enrollment into care and the start of
ART, particularly among patients who are not immediately
eligible to start treatment. In a systematic review of twenty-nine
studies from sub-Saharan Africa (SSA), only a quarter of patients
with HIV started ART, and loss to follow-up (LTF) was two times
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higher among patients not eligible for ART at enrollment
compared to eligible patients.[8] Predictors of LTF in pre-ART
patients have not been well characterized but male gender,[8–10]
younger age,[10] lower socioeconomic status,[8] and not being
married[11] have been cited as risk factors. Mortality rates
reported for pre-ART patients are high, with the greatest risk of
death among patients with advanced disease status at enrollment
in care.[9,12,13] LTF appears to be lower in patients on
ART,[9,14–17] although high rates of early mortality for patients
initiating ART have been reported, largely due to advanced
disease status at treatment initiation.[14,18–20] In addition to
starting ART with advanced HIV, factors associated with
mortality in patients on ART include male gender[14,20–22]
and older age.[20,23]
In this analysis we estimated LTF and mortality rates for both
pre-ART patients and patients on ART at HIV care and
treatment facilities in Rwanda and identified risk factors associated
with these outcomes. The data for the analysis come from
publically funded health facilities across Rwanda which received
support and technical assistance from ICAP, a non-governmental
organization based at Columbia University through funding from
the President’s Emergency Plan for AIDS Relief (PEPFAR). All
facilities included in this analysis participated in the Identifying
Optimal Models of HIV Care and Treatment Study
(5U2GPS001537-03) which uses routinely collected patient and
facility level data to assess patient and program outcomes.
Methods
Ethics Statement
This study is part of the Identifying Optimal Models of HIV
Care and Treatment in Rwanda Collaboration which was
approved by the Rwandan National Ethics Committee (RNEC),
the Columbia University Medical Center Institutional Review
Board (IRB), the US Centers for Disease Control and Prevention,
and President’s Emergency Fund for AIDS Relief (PEPFAR)
Office of the Global AIDS Coordinator (OGAC). The study is
based on secondary analysis of health information from electronic
databases at participating study sites. The study procedures did not
include any interaction with subjects. All data that are part of the
Optimal Models study are de-identified at health facilities; all
personal identifiers are removed and investigators have no access
to code books with identifiable patient information. Patients were
not asked to provide informed consent for the use of data as per
the approvals of the ethics boards listed above.
This analysis includes de-identified routinely-collected data on
HIV-infected adults (15 years and above) enrolled at 41 healthcare
facilities located in Kigali City and the western province of
Rwanda from January 2005 to September 2010. All facilities
received support from ICAP which has worked with the Rwandan
government and local partners since 2005 with funding from
PEPFAR. ICAP is a nongovernmental organization that supports
scale-up of HIV services through clinical mentorship of facility
staff, renovation of laboratory and healthcare facilities, creation
and support of monitoring and evaluation tools and practices, and
other technical assistance.
Data were collected by clinicians at participating health facilities
as part of routine medical care. Information from patient records
was entered into an electronic database at each of the health
facilities by trained data clerks. Data quality assessments were
conducted by ICAP support teams every 6 months to review
completeness and accuracy. All data were de-identified prior to
analysis.
National guidelines for HIV care and treatment services in place
during the study period recommended a comprehensive history,
physical examination and CD4+ lymphocyte cell count (CD4
count) at the first visit for HIV-positive patients enrolling in care.
For subsequent visits, the guidelines recommended twice yearly
evaluations and CD4 count monitoring for ART patients. The
frequency of evaluations and CD4 count monitoring for pre-ART
patients varied depending on CD4 count and evolved over time:
before 2009, quarterly evaluations and CD4 count monitoring for
patients with CD4 count below 500 and twice yearly for those
above 500. After 2009, evaluations were quarterly coupled with
twice yearly CD4 count and yearly viral load monitoring.[24,25]
Initially ART was prescribed according to national protocols by
physicians, and after the introduction of task shifting in 2011,
nurses were also able to initiate and monitor patients on ART.
Using the eligibility guidelines in place at the time patients were
enrolled in care, we classified patients according to their ART
eligibility based on CD4 count and WHO stage at enrollment.
Table 1 highlights the relevant ART eligibility guidelines in place
during the period of interest for the analysis. Patients missing
sufficient data at enrollment to determine ART eligibility were
classified as indeterminate. For the group of patients identified as
being indeterminate for ART eligibility at enrollment, we
conducted a sensitivity analysis reclassifying patients as ineligible
if they were missing CD4 count but were WHO stage I and II or if
they had CD4 count .350 but were missing WHO stage.
The study population for this analysis was adult patients $15
years with no history of ART at enrollment who entered care from
January 2005 to September 2010 at an ICAP-supported health
facility with an electronic database. Patients who enrolled in care
already on ART or with a history of treatment but not currently
on ART were excluded from this analysis. For clinical and
immunologic status at enrollment (WHO stage and CD4 count),
any value within 3 months before and one month after enrollment
was considered for the analysis. For patient characteristics at ART
initiation, we considered the closest value using a window period
of 3 months before and 1 month after the start date of ART.
Patients were considered LTF if they did not have a
documented death, withdrawal or transfer to another health
facility and were not active in care for 6 months for ART patients
and 1 year for pre-ART patients. For the pre-ART analyses,
patients were considered censored at their ART initiation date (if
they started treatment) or at the end of September 2011 if they did
not start ART during follow-up. For analyses of patients on ART,
patients were censored at the end of September 2011.Time to LTF
for pre-ART patients was defined as the time from enrollment to
the 90 days after the last visit and for ART patients was defined as
time from ART initiation to 15 days after the last visit.
Information on deaths came from documentation in patient
health records at the facilities. Time to death was defined as the
time from enrollment for the pre-ART analysis or from ART start
date until the documented date of death. Patients who had
documentation of transfer out of care were censored at the date of
transfer or last visit date.
LTF and mortality were modelled for the pre-ART analysis
using follow-up time and outcomes for patients enrolled in care
prior to ART initiation. Some patients started treatment on the
day of enrollment and did not contribute time to the pre-ART
analyses. Patients who did not start ART on the day of enrollment
were included in the pre-ART analyses and include those who did
not start treatment either because they did not reach eligibility
during follow-up or did become eligible but did not initiate ART.
Multivariable relative risk regression was used to assess factors
associated with initiation of ART during follow-up. Multivariable
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log-binomial models of ART initiation were adjusted for age, sex,
WHO stage and CD4 count at enrollment. Generalized estimating
equations were used to generate robust standard errors to account
for correlated observations among patients at the same health
facilities.
For pre-ART analyses, because patients were censored at ART
initiation, this event is an important competing risk for LTF and
death. Cumulative incidence of LTF and death were generated
using competing risk estimators for patients in the pre-ART
period, whereas probabilities of LTF and death using Kaplan-
Meier estimators are reported for patients on ART. Competing
risks regression was applied to calculate the sub-distribution
hazard ratios (SHR) to measure the association between baseline
characteristics and LTF and death for pre-ART patients. For
analysis of pre-ART LTF, both ART initiation and death were
considered competing risks for LTF; for mortality outcomes, ART
initiation was considered a competing risk for death.[26] For
analysis of LTF and mortality among ART patients, only follow-
up time after the ART start date for patients who initiated
treatment was included and standard Cox regression was used to
calculate hazard ratios. For both pre-ART and ART analysis, a
robust variance estimate was used to adjust for within-site
correlations.[27,28] For multivariable models, we adjusted for
selected covariates (baseline patient and facility characteristics)
that a priori were considered important predictors of LTF and
death. All analyses were conducted using SAS 9.3 and Stata 12.1.
Results
Between January 2005 and September 2010, a total of 31,033
HIV-infected ART-naı̈ve adults $15 years were enrolled in care
at 41 ICAP-supported health care facilities in Rwanda. The
median age at enrollment was 34 years, the majority (64.2%) were
women, and 62.1% of patients were enrolled through voluntary
counselling and testing services (Table 2). Among all adults
enrolled, 15.5% were single, 59.1% of patients were married and
20.0% were widowed. Roughly half of the patients (55.4%) were
enrolled at health facilities in urban areas.
WHO stage and CD4 counts were missing for 19.2% and
14.8% of patients at enrollment, respectively (Table 2); 1373
(4.4%) patients were missing both WHO stage and CD4 count at
enrollment. Among patients with WHO stage at enrollment,
75.3% were WHO stages I and II, and 2.3% were WHO stage IV.
At enrollment, 54.6% of patients with CD4 count results had a
CD4 count .350 while 10.5% had CD4 count ,100 (Table 1).
Based on CD4 count and WHO stage, 32.7% of all patients were
eligible for ART at enrollment, 43.1% were not eligible and 24.2%
were indeterminate based on Rwanda’s national guidelines for
ART initiation at the time of enrollment. In the sensitivity analysis
33.9% were eligible, 57.9% were ineligible, and 8.2% were
indeterminate (the sensitivity analysis reclassified patients with
WHO stage I & II missing CD4 count and those with CD4 count
.350 missing WHO as ineligible whereas for the main analysis
they were considered indeterminate for ART eligibility).
Among all 31,033 enrolled patients, 17,212 (55.5%) started
ART, while 13,821 (44.5%) did not initiate ART during follow-up
(Table 2). In multivariable models of the factors associated with
initiating ART, CD4 count at enrollment was the strongest
predictor: CD4 100–199 vs. .350 adjusted risk ratio (ARR) 2.71
(95%CI: 2.6–2.9); CD4,100 vs. .350 ARR 2.62 (95%CI: 2.5–
2.8). Younger patients were significantly less likely to start
treatment (15–20 vs. 31–40 years of age ARR 0.8, 95%CI: 0.7–
0.9; 21–30 vs. 31–40 AOR 0.9, 95%CI: 0.8–0.9).
The average duration of follow-up for all enrolled patients was
951 days (range: 0–2,463 days); 434 days (range: 0–2,463 days) for
patients in the pre-ART period and 932 days (range: 0–2,452) for
patients who were on ART. Overall, 4,317 (13.8%) of all enrolled
patients were LTF and 2,044 (6.5%) died. A total of 674 (2.2%)
patients started ART on the day of enrollment and thus did not
contribute person time to the pre-ART analyses.
Cumulative LTF and mortality rates
The cumulative LTF rate in pre-ART patients at 6, 12, 24, and
36 months after enrollment was 6.6% (95%CI 6.3–6.9), 8.6%
(95%CI 8.3–9.0), 11.2% (95%CI 10.9–11.6), and 12.7% (95%CI
12.3–13.1), respectively (Figure 1). Among the pre-ART patients,
cumulative mortality after enrollment was 1.6% (95%CI 1.5–1.7)
at 6 months, 2.2% (95%CI 2.0–2.4) at 12 months, 2.9% (95%CI
2.7–3.1) at 24 months, and 3.3% (95%CI 3.1–3.6) at 36 months
(Figure 1).
In patients who initiated ART, LTF at 6, 12, 24 and 36 months
was 1.9% (95%CI 1.8–1.9), 2.9% (95%CI 2.8–2.9), 4.4% (95%CI
4.4–4.5), and 5.5% (95%CI 5.4–5.5), respectively (Figure 2).
Cumulative mortality among ART patients was 3.4% (95%CI
3.4–3.5) at 6 months, 4.7% (95%CI 4.7–4.8) at 12 months, 6.3%
(95%CI 6.2–6.4) at 24 months and 7.4% (95%CI 7.2–7.4) at 36
months, respectively (Figure 2).
Factors associated LTF and Mortality in Pre-ART patients
Among pre-ART patients, LTF was associated with male
gender (adjusted sub-distributional hazard ratio (aSHR) 1.3,
95%CI 1.1–1.5) and younger age (21–30 vs. 31–40 years aSHR
1.5, 95%CI 1.3–1.6) while being married was protective (married
vs. single aSHR 0.8, 95%CI 0.6–0.9) (Table 3). LTF was also
associated with less advanced disease status in pre-ART patients.
Low CD4 count was protective against LTF (CD4,100 vs. $350
aSHR 0.2, 95%CI 0.1–0.3) as was higher WHO stage (WHO
stage IV vs. stage I aSHR 0.4, 95%CI 0.2–0.6) (Table 3).
In pre-ART patients, men had significantly higher mortality
than women (aSHR 1.7, 95% CI: 1.4–2.1) (Table 3). Older pre-
ART patients also had higher hazard of death than younger
patients; those older than 60 years were 2.2 times more likely to
die compared to patients aged 31–40 years (95% CI 1.5–3.2). Pre-
ART patients with WHO stage III or IV were 3.5 (95%CI 2.6–
4.7) and 7.1 (95%CI 5.0–10.2) times more likely to die prior to
ART initiation compared to patients with WHO stage I,
respectively (Table 3). Compared to patients with CD4 count
$350, pre-ART patients with CD4 count ,100 had significantly




WHO stage 4 regardless of CD4+
CD4+ ,200/mm3
CD4+ 200–350 and WHO stage 3
WHO stage 4 regardless of CD4 cell count CD4
cell count ,350/mm3 regardless of WHO stage
doi:10.1371/journal.pone.0085774.t001
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Table 2. Demographic and clinical characteristics at enrollment of HIV-infected adults at 41 ICAP supported health facilities in
Rwanda, January 2005-September 2010 (N = 31,033).
All patients Patients initiating ART
Adult patients N = 31033 % N = 17212 %
Age (years), median (IQR) 34.2 (27.8–41.8) 35.99 (29.7–43.2)
15–20 931 3.0 332 1.9
21–30 9494 30.6 4170 24.2
31–40 11205 36.1 6630 38.5
41–50 6623 21.3 4325 25.1
51–60 2139 6.9 1362 7.9
.60 641 2.1 403 2.3
Sex
Male 11107 35.8 6438 37.4
Female 19926 64.2 10774 62.6
Marital status
missing 7857 25.3 3965 23.0
Single 3602 15.5 1710 12.9
Married/in union 13701 59.1 7707 58.2
Widowed 4625 20.0 3110 23.5
Divorced or separated 1248 5.4 720 5.4
Point of entry into care
Voluntary counselling and testing 19267 62.1 10917 63.4
PMTCT 6332 20.4 2995 17.4
TB/HIV 106 0.3 67 0.4
Inpatient 1573 5.1 944 5.5
Outpatient 1395 4.5 877 5.1
Other/known 2360 7.6 1412 8.2
WHO Stage
missing 5945 19.2 2791 16.2
Stage I 11555 46.1 5168 35.8
Stage II 7344 29.3 4611 32.0
Stage III 5624 22.4 4188 29.0
Stage IV 565 2.3 454 3.2
CD4 count (cells/mL), median (IQR) 385 (208–605) 258 (143–388)
missing 4583 14.8 2090 12.1
,100 2782 10.5 2430 16.1
100–199 3498 13.2 3185 21.1
200–350 5738 21.7 4887 32.3
350+ 14432 54.6 4620 30.6
ART eligibility at enrollment
Eligible 10158 32.7 9022 52.4
Ineligible 13372 43.1 5095 29.6
Indeterminate 7503 24.2 3095 18.0
Calendar year of enrollment
2005 4980 16.1 3019 17.5
2006 6423 20.7 3847 22.4
2007 6290 20.3 3487 20.3
2008 5435 17.5 2963 17.2
2009 4892 15.8 2483 14.4
2010 3013 9.7 1413 8.2
Facility type
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higher hazard of death (aSHR 1.5, 95%CI 1.1–2.0). Among pre-
ART patients, mortality was also associated with attending a
facility in a rural area (aSHR 1.7, 95% CI 1.2–2.3). Patients
missing information on marital status, CD4 count and WHO stage
were also at higher risk of death in adjusted models (Table 3).
Factors associated with LTF and mortality in ART patients
In ART patients, LTF was associated with male gender
(adjusted hazard ratio (aHR) 1.4, 95%CI 1.2–1.7) and younger
age (21–30 years vs. 31–40 aHR 1.4, 95%CI 1.2–1.7). Being
married was protective against LTF in ART patients (married vs.
single aHR 0.6, 95%CI 0.4–0.9) (Table 4). ART patients with
lower CD4 counts were less likely to be LTF than those with low
CD4 counts (CD4 ,100 vs. $350 aHR 0.64, 95%CI 0.4–0.9).
WHO stage was not a significant predictor of LTF for patients on
treatment (Table 4).
Among ART patients, men had significantly higher mortality
than women (aHR 1.3, 95%CI 1.2–1.5). Compared with ART
patients 31–40 years of age, those older than 40 years had higher
hazard of death which increased with each decade of advancing
age (.60 years vs. 31–40 aHR 3.1, 95%CI 2.4–4.0) (Table 4).
WHO stage and CD4 count were both strong predictors of
mortality in ART patients; there was an eight fold higher hazard
of death for WHO stage IV vs. stage I (aHR 8.4, 95%CI 5.2–13.4)
and twice the hazard of mortality for CD4 count ,100 vs. $350
(aHR 2.1, 95%CI 1.5–2.9). Mortality in ART patients was also
associated with enrolling in care at rural health facilities (aHR 1.5,
95% CI 1.1–2.1) (Table 4).
Discussion
This is the largest report of outcomes for patients on ART from
Rwanda and the only report that we are aware of with data on
LTF and mortality in Rwandan patients with HIV prior to ART
initiation. We found low rates of LTF and mortality in adults in
Rwanda in the pre-ART period and after the initiation of
treatment. LTF in pre-ART patients at two-years was 11.2%
(95%CI, 10.9–11.6%) and mortality was 2.9% (95%CI 2.7–3.1%).
In adults on ART, two-year cumulative LTF and mortality were
4.4% (95%CI 4.4–4.5%) and 6.3% (95%CI 6.2–6.4%), respec-
tively. We also identified risk factors associated with LTF and
mortality in both pre-ART and patients on ART which included
male gender and disease status.
We found very low rates of mortality among patients who were
not on ART in this cohort from Rwanda. Much of the existing
data on mortality in the pre-ART period is restricted to patients
eligible for treatment at enrollment based on immunologic and
clinical disease status. Those previous analyses in patients with
advanced disease have found very high mortality, 28% in a report
Figure 1. Cumulative incidence of LTF and mortality among
pre-ART adult patients in Rwanda (N = 31,033). Patients were
counted as LTF starting at 90 days after the enrollment visit, as a result
the cumulative incidence for LTF starts at this point rather than time 0
on figure.
doi:10.1371/journal.pone.0085774.g001
Figure 2. Kaplan-Meier estimates of LTF and mortality among
adults on ART in Rwanda (N = 17,212).
doi:10.1371/journal.pone.0085774.g002
Table 2. Cont.
All patients Patients initiating ART
Adult patients N = 31033 % N = 17212 %
Primary 9870 31.8 5463 31.7
Secondary 14304 46.1 8040 46.7
Other 6859 22.1 3709 21.6
Setting
Urban (15 sites) 17197 55.4 9411 54.7
Rural (26 sites) 13836 44.6 7801 45.3
doi:10.1371/journal.pone.0085774.t002
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from Uganda[9] and 34% in patients in South Africa.[17] Our
analysis included outcomes during the period prior to ART
initiation for all enrolled patients, both ART-eligible and -
ineligible, and we would expect to find lower mortality in this
combined group, particularly given the general good health of our
cohort at enrollment. Our low estimate of mortality for the pre-
ART period must also be considered with regard to missing
information on deaths which may have led to misclassification of
some subjects. It is possible that due to missing data on deaths,
some patients who died may have been misclassified as LTF which
could have artificially lowered our estimated mortality and
increased LTF. It has been noted, primarily in cohorts of patients
on ART, that up to half of all patients who are LTF have
died.[29–31] Even if we assume some misclassification of deaths as
Table 3. Demographic and clinical characteristics at enrollment associated with LTF and death among pre-ART patients at 41 ICAP
supported health facilities in Rwanda, January 2005-September 2010 (N = 31,033).
LTF Death
Adult patients SHR 95% CI ASHR* 95% CI SHR 95% CI ASHR* 95% CI
Gender
Male 1.0 0.9–1.2 1.3 1.1–1.5 1.7 1.4–2.1 1.7 1.4–2.1
Age category
15–20 2.6 2.1–3.2 2.0 1.6–2.4 0.7 0.5–1.1 0.8 0.5–1.3
21–30 1.8 1.6–2.0 1.5 1.3–1.6 0.8 0.7–1.0 1.0 0.9–1.2
31–40 1 Reference 1 Reference 1 Reference 1 reference
41–50 0.8 0.7–0.9 0.8 0.7–1.0 1.2 1.0–1.5 1.0 0.8–1.2
51–60 0.7 0.6–0.9 0.8 0.7–1.0 1.5 1.1–2.0 1.3 0.9–1.7
60+ 0.8 0.5–1.1 0.9 0.7–1.2 3.0 2.1–4.4 2.2 1.5–3.2
Marital status
Single 1 Reference 1 Reference 1 Reference 1 Reference
Married/in union 0.6 0.5–0.7 0.8 0.6–0.9 1.0 0.8–1.3 0.8 0.6–1.1
Divorced/separate 0.5 0.4–0.7 0.7 0.6–1.0 1.8 1.2–2.6 1.6 1.1–2.4
Widowed 0.3 0.3–0.4 0.6 0.5–0.7 1.4 1.1–1.8 1.1 0.8–1.5
missing 1.1 0.9–1.5 1.5 1.1–1.9 2.0 1.1–3.1 1.6 0.9–2.8
WHO Stage
Stage I 1 Reference 1 Reference 1 Reference 1 Reference
Stage II 0.6 0.4–0.7 0.7 0.6–0.9 1.6 1.2–2.1 1.4 1.1–1.8
Stage III 0.4 0.3–0.5 0.6 0.5–0.9 4.8 3.7–6.1 3.5 2.6–4.7
Stage IV 0.2 0.1–0.3 0.4 0.2–0.6 10.9 8.0–14.9 7.1 5.0–10.2
missing 1.1 0.8–1.5 1.2 0.9–1.7 3.8 2.4–5.9 3.0 2.0–4.6
CD4 count
,100 0.2 0.1–0.2 0.2 0.1–0.3 2.8 2.2–3.7 1.5 1.1–2.0
100–199 0.2 0.1–0.2 0.2 0.2–0.3 1.0 0.8–1.4 0.7 0.5–1.0
200–349 0.3 0.2–0.4 0.4 0.3–0.5 0.8 0.6–1.0 0.7 0.5–0.8
$350 1 Reference 1 Reference 1 Reference 1 Reference
missing 1.1 1.0–1.3 1.1 0.9–1.3 2.5 1.8–3.4 1.8 1.3–2.4
Calendar year of enrollment
2005 1.2 0.6–2.4 1.1 0.5–2.1 3.1 1.9–5.2 1.5 0.9–2.7
2006 1.3 0.8–2.1 1.3 0.7–2.2 2.7 1.7–4.5 1.6 0.9–2.7
2007 1.2 0.9–1.8 1.3 0.9–1.8 2.7 1.8–4.1 1.9 1.2–3.0
2008 1.1 0.9–1.5 1.2 0.9–1.6 2.0 1.4–2.8 1.5 1.1–1.9
2009 1.1 0.9–1.4 1.2 1.0–1.4 1.3 0.8–2.0 1.2 0.7–1.9
2010 1 Reference 1 Reference 1 reference 1 Reference
Facility type
Primary 0.7 0.4–1.3 0.8 0.6–1.2 0.8 0.6–1.2 0.8 0.6–1.1
Setting
Rural 0.8 0.4–1.3 0.8 0.5–1.4 1.5 1.0–2.2 1.7 1.2–2.3
*Adjusted for all the other variables in the table.
Bolded figures were statistically significant at p,0.05.
doi:10.1371/journal.pone.0085774.t003
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LTF, however, the mortality rate in this pre-ART cohort is still
very low. These results suggest that Rwandan HIV care and
treatment facilities may be rapidly initiating the sickest patients
onto ART resulting in lower mortality among those patients not
immediately initiating treatment.
Compared to mortality, pre-ART patients had higher rates of
LTF, roughly 9% in the first year in care and 11% by the end of
year two. Outcomes of patients who are LTF are by definition not
known and, as noted above, some of these patients may have in
fact died resulting in an overestimate of LTF and underestimate of
mortality in this analysis. While some amount of misclassification is
likely, the findings of low mortality and higher LTF may also
reflect the general health of the patients who enrolled in care at
these Rwandan sites, three quarters of whom were WHO stage I
Table 4. Demographic and clinical characteristics at ART-initiation associated with LTF and death among ART patients at 41 ICAP
supported health facilities in Rwanda, January 2005-September 2010 (N = 17,212).
LTF Death
Adult patients HR 95% CI AHR* 95% CI Crude HR 95% CI AHR* 95% CI
Gender
male 1.2 1.1–1.5 1.4 1.2–1.7 1.6 1.4–1.8 1.3 1.2–1.5
Age at ART Initiation
15–20 1.7 1.0–2.9 1.2 0.7–2.2 1.2 0.8–2.0 1.1 0.6–2.0
21–30 1.6 1.3–1.9 1.4 1.2–1.7 0.7 0.6–0.9 0.9 0.7–1.1
31–40 1 Reference 1 reference 1 Reference 1 Reference
41–50 0.8 0.7–1.0 0.8 0.7–0.9 1.6 1.4–1.8 1.4 1.2–1.6
51–60 0.8 0.5–1.1 0.8 0.6–1.1 2.0 1.6–2.5 1.8 1.4–2.2
.60 0.7 0.4–1.1 0.8 0.4–1.4 3.6 2.9–4.6 3.1 2.4–4.0
Marital status
Single 1 Reference 1 reference 1 Reference 1 Reference
Married/in union 0.5 0.3–0.6 0.6 0.4–0.9 1.0 0.8–1.3 0.9 0.6–1.2
divorced/separate 0.5 0.3–0.8 0.7 0.4–1.3 1.3 0.9–2.0 1.1 0.8–1.6
Widowed 0.4 0.3–0.5 0.7 0.5–0.9 1.3 1.1–1.7 1.0 0.7–1.3
missing 0.7 0.5–1.1 1.1 0.8–1.5 2.0 1.3–3.2 1.7 1.0–3.0
WHO Stage at enrollment
Stage 1 1 Reference 1 reference 1 Reference 1 Reference
Stage II 0.9 0.6–1.4 1.0 0.6–1.6 2.3 1.5–3.5 1.8 1.2–2.8
Stage III 0.9 0.6–1.2 1.0 0.7–1.5 5.4 3.6–7.9 3.2 2.2–4.3
Stage IV 1.7 1.2–2.3 1.7 1.0–2.9 15.1 9.1–25.1 8.4 5.2–13.4
missing 0.9 0.7–1.3 1.0 0.7–1.4 2.8 1.8–4.3 2.2 1.5–3.3
CD4 count
,100 0.6 0.4–0.8 0.6 0.4–0.9 2.6 1.9–3.5 2.1 1.5–2.9
100–199 0.6 0.4–0.8 0.7 0.5–0.9 1.1 0.8–1.5 1.0 0.8–1.4
200–349 0.6 0.5–0.7 0.6 0.5–0.8 0.6 0.4–0.9 0.6 0.4–0.9
$350 1 Reference 1 reference 1 Reference 1 Reference
missing 0.7 0.5–1.0 0.8 0.5–1.2 1.9 0.9–3.6 1.6 0.9–2.8
Calendar year of enrollment into care
2005 0.3 0.1–1.0 0.3 0.1–0.9 2.8 2.1–3.8 1.3 0.9–1.7
2006 0.6 0.3–1.1 0.5 0.3–1.0 1.9 1.4–2.5 1.0 0.8–1.4
2007 0.5 0.3–0.7 0.5 0.3–0.7 1.7 1.4–2.2 1.1 0.9–1.5
2008 0.5 0.4–0.7 0.6 0.4–0.8 1.4 1.1–1.8 1.2 0.9–1.5
2009 0.7 0.6–0.9 0.7 0.6–0.9 1.3 1.0–1.7 1.1 0.9–1.5
2010 1 Reference 1 reference 1 reference 1 Reference
Facility type
Primary 0.7 0.4–1.3 0.7 0.5–1.2 0.8 0.6–1.1 0.9 0.7–1.1
Setting
Rural 0.5 0.2–1.0 0.6 0.3–1.2 1.4 1.0–1.9 1.5 1.1–2.1
*Adjusted for all the other variables in the table.
Bolded figures were statistically significant at p,0.05.
doi:10.1371/journal.pone.0085774.t004
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or II at enrollment. In our analysis, we found that LTF was more
likely among pre-ART patients with high CD4 counts and less
advanced clinical stage. Similar findings were reported by Lessells
et al from a pre-treatment cohort in rural South Africa in which
LTF was also associated with better health status.[10] Although
there are few reports of patient outcomes prior to ART initiation
and more data are needed to understand the reasons why patients
with better health status are LTF, it may be that patients who are
healthy at enrollment have less incentive to remain in care. It is
clear that HIV care and treatment programs must make greater
efforts to retain patients in care prior to ART initiation,
particularly among those who are in good health at enrollment,
so that they can start ART promptly when they become eligible.
LTF and mortality were also low for patients on ART in this
cohort; two year cumulative LTF was 4.4% and mortality was
6.3%. These findings are in keeping with previous reports from
smaller cohorts of patients on ART in Rwanda. Lowrance et al
found 4.9% LTF and 4.6% mortality at 12 months in patients who
initiated ART in Rwanda from 2004 to 2005.[2] Recently
published data on 1,041 patients from the Partners in Health
implementation project in Rwanda reported LTF of 2.7% and 5%
mortality over two years.[32] Our findings, together with those
from previous analyses, show that LTF and mortality in ART
patients in Rwanda are lower than those reported from many
other sub-Saharan African settings. A recent analysis of data from
13 African countries estimated that only 60% of patients are
retained in care after two years on treatment in many resource
limited settings.[33]
We believe the consistency of good patient outcomes across
treatment cohorts and from different implementation programs in
Rwanda is evidence of the strengths of the Rwandan national HIV
care and treatment program. The government of Rwanda was one
of the first countries to implement free publically available ART
starting in January 2004[2] and has been at the forefront of
implementing evidence-based interventions aimed at expanding
access and improving patient outcomes, including decentralization
of care and treatment services,[5] nurse-initiated ART,[3,6] and
revising treatment eligibility criteria to start patients on ART at
earlier stages of disease.[25] The patients included in this analysis
were also found to initiate ART at a higher median CD4 count
than has been found across other low and middle-income
countries.[34] All of these factors may have contributed to the
high rates of retention and low mortality found among patients
enrolled in care and treatment programs in Rwanda. In addition,
recent data from a nationally representative cross sectional study
in Rwanda found high rates of adherence and viral suppression in
patients on ART.[35]
The risk factors for LTF and mortality identified in this analysis
were similar between pre-ART and ART patients, and were in
keeping with previous studies. In multivariable models we found
that LTF in pre-ART patients was associated with male gender,
younger age, not being married and having better immunologic
and clinical status, all of which are similar to findings from
previous analyses.[8–11] Higher pre-ART mortality was found in
men, older patients and those with more advanced disease status.
As noted, the few previous studies with mortality outcomes for pre-
ART patients have focused on those with advanced disease status.
While we included both eligible and ineligible pre-ART patients,
we have identified similar factors associated with mortality as those
from previous reports, including male gender[9] and advanced
disease status.[17] Similar to the pre-ART patients, LTF in
patients on ART was higher among those who were male,
younger, not married and in those who had higher CD4 counts.
Mortality in ART patients was also associated with male gender,
as well as older age and more advanced disease status. Our
findings on risk factors for both LTF and death among patents on
ART were similar to those from previous reports.[14,15,18,21]
[36]
The primary strength of this analysis is the large cohort size,
31,033 patients, and more than five years of follow-up. The cohort
was drawn from a larger number of health facilities which
represent the range of locations and facility types where most
patients in Rwanda receive care, from rural primary health
facilities to urban tertiary hospitals. The patients included in this
analysis represent roughly 24% of all adults enrolled in HIV
services in Rwanda by the end of September 2010. A critical asset
to this report is the inclusion of patient outcomes in the period
prior to the initiation of ART. There is a paucity of data on
outcomes in the pre-ART period from resource limited setting and
no previous reports of pre-ART cohorts from Rwanda. This paper
provides important findings on retention and mortality for pre-
ART patients, as well as the factors associated with these
outcomes.
The main limitation of this study, as with similar analyses
utilizing routinely collected health record information, is missing
data. Overall 15% of patients were missing CD4 count and 19%
were missing WHO stage at enrollment. While Rwandan health
facilities have more complete data than has been found in
treatment program in other RLS,[16] because disease status was a
strong predictor of both LTF and mortality in pre-ART patients,
the missing data on CD4 count and WHO are an important
limitation of our analysis. It is not known whether some or all of
the missing data were actually missing in the medical records at
the facilities and thus were not available for providing clinical care
or whether the data are only missing from the study dataset. If the
data were missing in the medical records, this could have had an
impact on the provision of clinical care and identifying all those
eligible for ART. An additional limitation of the Optimal Models
study is that it only includes patient data collected as part of
routine service delivery and as such we could not evaluate certain
patient level factors that have been associated with retention
previously, such as distance patients travel from their homes to
facilities and education level,[11] which are not available in our
dataset.
Overall, we found low mortality rates in both pre-ART and
ART patients and high retention of patients on ART in Rwanda
in our analysis of routinely-collected data from 41 ICAP-supported
health facilities. These results show that high retention and low
mortality are possible both before and after initiation of ART in
RLS. They also suggest that greater efforts must be made by HIV
service programs to retain patients in care prior to ART initiation,
particularly for patients who are healthy and not eligible for
treatment at the time of enrollment.
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